New research reveals that individuals who discontinue new weight-loss injections like semaglutide or tirzepatide tend to recover lost weight at a significantly accelerated pace than those who halt traditional lifestyle plans.
Published data in a leading health publication demonstrates that while overweight individuals often shed substantial amounts of their total mass while on the medication, the weight returns at an estimated rate of nearly a kilo each month after stopping.
"People using such treatments must be cognizant of the danger of rapid weight regain when the treatment concludes," warns researcher Dr. Susan Jebb.
Such speed of recovery implies a return to starting mass in about a year and a half.
Comparing Treatments
The research, which looked at dozens of trials involving thousands of participants, compared the outcomes of GLP-1 agonists with other pills.
Researchers note that people who lose weight through dieting typically see a slower weight regain—approximately 100 grams monthly—post-intervention.
Explaining the Rapid Regain
Doctors propose the mechanism of the drugs explains the heightened rebound.
These medications copy a body's own chemical called glucagon-like peptide-1, which controls hunger.
"Long-term administration of GLP-1 concentrations far above than the body's typical production might result in the body to produce less of its own natural hormone, and could lessen sensitivity to its actions," explained Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this medication results in hunger is uncontrolled, making overeating a significant risk."
A Lifelong Condition?
Medical guidelines advise the injections for people with obesity-related health risks, accompanied by prescribed diet and exercise modifications.
A number of clinicians say that, considering the high risk of relapse, the treatment should be considered long-term.
This view is echoed by pharmaceutical companies, who state that the results "underscore the long-term character of excess weight," akin to managing conditions like hypertension.
User Accounts
Individuals who have discontinued the jabs describe a powerful return of cravings.
"I experienced a switch flipping and I was suddenly extremely hungry," recalled a patient.
This challenge is exacerbated if patients have not established permanent dietary or behavioural modifications during treatment.
Widespread Use
Survey data indicate that a significant number of people in the UK have tried weight-loss jabs in the past year, with interest remaining high.
- Adoption is greater among women compared to men.
- The 40s and 50s age group shows the highest usage rates.
- Many access the drugs through private prescriptions rather than the NHS.
In conclusion, researchers stress that while these medications are potent tools for shedding pounds, they are not a magic fix and long-term success relies on ongoing lifestyle support.
